ClinicalTrials.gg
CompletedNCT03870945Updated May 28, 2025

Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)

A Phase 1 interventional study of MB-CART2019.1 Dose level 1 and MB-CART2019.1 Dose level 2 in B-cell Non Hodgkin Lymphoma, sponsored by Miltenyi Biomedicine GmbH. Completed at 3 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by Miltenyi Biomedicine GmbH · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 56 studies in Lymphoma, B-Cell with a site in Germany — 11 open to participants now, 23 under way, 9 of them phase 3. Lymphoma, B-Cell · Germany.

Enrollment
50th of 53
12 · median 111
Started
2019
with 6 others
Phase 1
12 of 56
1 open now
Registered
30th of 56
by date
Lead sponsor
5 of 56
Miltenyi Biomedicine GmbH

Among the 56 studies in Lymphoma, B-Cell with a site in Germany, this one is the 50th largest by enrollment of the 53 interventional ones that give a count, is one of 7 that started in 2019, is one of 12 in phase 1, and was the 30th registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

11 of the 56 studies in Lymphoma, B-Cell with a site in Germany are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Lymphoma, B-Cell with a site in Germany, or all of them as a file.
02

Study summary

This is a prospective, multi-center, open phase I/II trial to evaluate feasibility, dosage, safety and toxicity as well as efficacy of ex vivo expanded autologous T cells genetically modified to express anti-CD20 and CD19 immunoreceptor (MBCART2019.1) in patients with relapsed or resistant aggressive CD20 and CD19 positive B-NHL/CLL/SLL.

Read the detailed description

This trial will be performed as a multi-center phase I/II trial with MB-CART2019.1 and consists of part I. In part I, 12 to 18 patients with relapsed or resistant CD20 and CD19 positive NHL/CLL/SLL will be treated. Six plus three (6+3) patients in dose level 1 and 2 will be treated.

The trial will be conducted in Hematology Departments of Hospitals which meet the structural and personnel requirements for performing the planned regular trial-related investigations. Only sites will be chosen with expertise in and necessary facilities for managing cytokine release storm and other severe adverse events associated with this therapy such as neurotoxicity. A corresponding training to site personnel prior to trial start must be performed. The responsible intensive care unit (ICU) must be informed about the clinical trial before inclusion of the first patient and the respective dosing date in order to make sure that the medical staff of the ICU is able to react appropriately without any loss of time in case of emergency. The University Hospital of Cologne will provide the Coordinating Investigator. Additional clinical sites may be added during the trial.

Patients will be screened between day -30 and day -15. If the patient satisfies all the protocol inclusion and none of the exclusion criteria, he/she will be included in the clinical trial. Leukapheresis will be performed at the collection center on day -14 according to local standard practice. The leukapheresis product of the patient will be shipped by a special courier to the designated manufacturing center assigned by the sponsor. The leukapheresis sample will be used for the individual manufacturing of MB-CART2019.1 by using the automated CliniMACS Prodigy® System. The manufacturing of MB-CART2019.1 will start on day -13 and will be finished on day -1.

On day 5 of the manufacturing process the IPC (in-process-control) will indicate, if the manufacturing process is successful. Therefore, the lymphodepleting chemotherapy must only be started after the positive result of the IPC was confirmed by the manufacturer. Chemotherapy for lymphodepletion will be done on days -5 to -3.

Administration of MB-CART2019.1 will be performed on day 0 in the Hematology Departments of all sites. Patients will be followed up as inpatients until week 4 with close monitoring of their vital functions and lab parameters for signs of adverse events. In the second follow-up phase (week 4 until week 12), response will be assessed, and adverse events will be documented. A follow-up examination will be performed at week 12 (achievement of primary endpoint) and at month 12 which is considered end of trial or end of active part of the trial. In the long-term follow-up yearly until 5 years or patient's death, safety and response assessment as well as persistence of MBCART2019.1 will be performed. These assessments will be analyzed and reported separately and are not part of the entire clinical trial. This is a 6+3 trial design with a 0.3 log dose increment (1x106/2.5x106 MBCART2019.1 per kg BW in a single infusion) and maximum 2 dose levels. If none or one of the six patients at dose level 1 experiences a dose limiting toxicity, another six patients will be treated at dose level 2. If two DLTs are observed at dose level 1 another three patients will be treated with the same dose. If more than two DLTs are observed at dose level 1, trial will continue at dose level 0. Dose escalation continues until at least >2 patients among a cohort of six to nine patients experience dose-limiting toxicities or dose level 2 is completed. The MTD is defined as the dose level below the dose inducing a DLT in more than 2 patients within one dose level. DLT will be evaluated within 4 weeks after the infusion of MB-CART2019.1. An interval of at least 28 days between the treatment of the first and the second patient in each dose level is mandatory. An observation period for DLT of 28 days is considered to be safe to exclude potential toxicities prior to inclusion of the next patients into the same dose group or prior to dose escalation.

03

Conditions studied

  • B-cell Non Hodgkin Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. /relapsed B-NHL (including malignant transformation like Richter's transformation) with no available approved standard therapy. Including, but not restricted to:

    1. Diffuse large B cell lymphoma (DLBCL): relapsed/refractory disease after or ineligible for ASCT after therapy; transformation from CLL, SLL or FL allowed
    2. Follicular lymphoma: at least 2 prior regimens and progression \<2 years after most recent line of therapy
    3. Mantle cell lymphoma: beyond 1st CR with relapsed disease, progressive disease during first-line rituximab chemotherapy, or persistent disease after first-line rituximab-chemotherapy and not eligible or appropriate for conventional therapy, ASCT or relapsed after prior autologous SCT, prior therapies including ibrutinib if not
    4. CLL and SLL: after at least two lines of treatment including btk inhibitor ibrutinib and bcl2 inhibitor venetoclax (if not contraindicated), patients must have been refractory to at least one of the substances

    Patients with criteria 1b-d will only be eligible for Part I, dose cohort 1.

  2. Patients in cohort 1a must have confirmed DLBCL and associated subtypes with relapse or refractory disease after first line chemo-immunotherapy and be ineligible for HSCT
  3. Histologically confirmed DLBCL and associated subtypes, defined by WHO 2016 classification:

    • DLBCL not otherwise specified (NOS)
    • High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology (DHL/THL) and FL3B
    • Aggressive B-cell lymphoma
    • T-cell/histocyte rich B-cell lymphoma
    • Primary mediastinal B-cell lymphoma
    • EBV+ DLBCL
    • Transformed lymphoma (e.g. transformed follicular or marginal zone lymphoma)
  4. First line chemo-immunotherapy is defined as therapy containing the combination of CD20 targeted immunotherapy and cytotoxic chemotherapy.
  5. Chemotherapy-refractory disease is defined as one or more of the following:

    • No response to first line of therapy

      • PD as best response to first line therapy regimen
      • SD as best response after 4 cycles of first line therapy
    • Disease progression or relapsed ≤12 months of first line therapy (must have proven recurrence in relapsed individuals)
  6. Ineligibility for HSCT is defined as having ONE of the following criteria:

    • Age based on country-specific definition
    • Impaired pulmonary function (DLCO or ≤60%)
    • Impaired cardiac function ( \<50%)
    • Impaired renal function ( \<60 mL/min)
    • Impaired hepatic function (/ALT >3 x , >1.5 x ULN or patient's baseline)

    In addition, all patients must fulfil the following criteria:

  7. Age ≥18 years
  8. according to Lugano criteria
  9. CD19 or CD20 tumor expression is not required after first line chemo-immunotherapy.

    1. Must have archival tissue available, if received CD19 targeted therapy or CD20 antibody, archival tissue must have been obtained subsequent to that therapy
    2. Must have at least 10 unstained slides of tissue available
    3. If archival tissue is not available, must be willing to undergo attempted repeat biopsy and fine needle Aspiration
  10. If has history of CNS disease, then must have:

    1. No signs or symptoms of CNS disease
    2. No active disease on magnetic resonance imaging (MRI)
    3. Absence of large cell lymphoma in cerebral spinal fluid (CSF) on cytospin preparation and flow cytometry, regardless of the number of white blood cells
  11. If has history of cerebral vascular accident (CVA):

    1. The CVA event must be >12 months prior to leukapheresis
    2. Any neurological deficits must be stable
  12. Estimated of >3 months other than primary disease
  13. No (i.e. , absence of menstrual bleeding for at least 1 year), hysterectomy, bilateral ovariectomy or tubal section/ligation) or negative pregnancy test at screening and before chemotherapy in women of childbearing potential. Sexually active female patients of childbearing potential should use one of the following highly effective methods of (Pearl index \<1%): hormonal contraceptives (oral, injected, implanted, transdermal), intrauterine devices or systems (e.g. hormonal and non-hormonal IUD), or vasectomized sexual partner for at least 1 month before the trial start, during the trial and in the 6 months following dosing. Male patients, unless surgically sterile (meaning at least two consecutive analyses following vasectomy demonstrate absence of sperms in the ejaculate), must be using two acceptable methods for contraception (e.g. spermicide and condom) during the trial and refrain from fathering a child throughout the trial and for up to 12 months after dosing
  14. Signed and dated before conduct of any trial-specific procedure

Exclusion criteria

Exclusion Criteria:

  1. (ECOG) performance status >2
  2. (ANC) \<1,000/µL
  3. count \<50,000/µL
  4. Absolute lymphocyte count \<100/µL
  5. Presence of leukemia/lymphoma cells in peripheral blood
  6. Primary CNS lymphoma
  7. Unable to give
  8. Known history of infection with (HIV) or active infection with (HGsAg positive)
  9. Known history of infection with virus unless treated and confirmed to be polymerase chain reaction (PCR) negative
  10. Known history or presence of seizure activities or on active anti-seizure medications within the previous 12 months
  11. Known history of CVA within prior 12 months
  12. Known history or presence of CNS disease, such as multiple sclerosis, optic neuritis or other immunologic or inflammatory disease
  13. Presence of CNS disease that, in the judgment of the investigator, may impair the ability to evaluate neurotoxicity
  14. Active systemic fungal, viral or bacterial infection
  15. Clinical heart failure with class ≥2 or \<30%
  16. Resting oxygen saturation \<90% on room air
  17. Liver dysfunction as indicated by total , and/or ALT >5 x institutional , unless directly attributable to patient's tumor
  18. \<30 mL/min calculated according to the modified formula of Cockcroft and Gault or by direct urine collection
  19. Pregnant or breast-feeding woman
  20. Active secondary requiring treatment
  21. Medical condition requiring prolonged use of systemic >10 mg/day
  22. Concurrent radiotherapy (allow up to time of leukapheresis)
  23. Baseline dementia that would interfere with therapy or monitoring, determined using mini-mental status exam at baseline
  24. History of severe immediate reaction against any drug or its ingredients/impurities that is scheduled to be given during trial participation e.g. as part of the mandatory lymphodepletion protocol, premedication for infusion, or rescue medication/salvage therapies for treatment related toxicities
  25. Patients in which such medication (see exclusion criterion 24) is for other reasons than hypersensitivity (e.g. and fludarabine)
  26. Refusal to participate in CAR-T long-term follow-up (LTFU).
  27. Refusal to undergo core needle or fine needle aspiration of tumor on day 2-5 after MB-CART infusion and at time of disease progression and relapse
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Dose level 1 with 1x10^6 MBCART2019.1 per kg BW

    The IMP will be administered as an intravenous infusion. This is a 6+3 trial arm with 1x10\^6 MBCART2019.1 per kg BW in a single infusion. If none or one of the six patients at dose level 1 experiences a dose limiting toxicity, another six patients will be treated at dose level 2. If two DLTs are observed at dose level 1 another three patients will be treated with the same dose. Dose escalation continues until at least \>2 patients among a cohort of six to nine patients experience dose-limiting toxicities or dose level 2 is completed. The MTD is defined as the dose level below the dose inducing a DLT in more than 2 patients within one dose level.

    Biological: MB-CART2019.1 Dose level 1

  • Experimental
    Dose level 2 with 2.5x10^6 MBCART2019.1 per kg BW

    The IMP will be administered as an intravenous infusion. This is a 6+3 trial arm with 2.5x10\^6 MBCART2019.1 per kg BW in a single infusion and maximum 2 dose levels. If none or one of the six patients at dose level 1 experiences a dose limiting toxicity, another six patients will be treated at dose level 2. If two DLTs are observed at dose level 1 another three patients will be treated with the same dose. If more than two DLTs are observed at dose level 1, trial will continue at dose level 0. Dose escalation continues until at least \>2 patients among a cohort of six to nine patients experience dose-limiting toxicities or dose level 2 is completed. The MTD is defined as the dose level below the dose inducing a DLT in more than 2 patients within one dose level.

    Biological: MB-CART2019.1 Dose level 2

Interventions

  • BiologicalMB-CART2019.1 Dose level 1

    This is a prospective, multi-center, open phase I/II trial to evaluate feasibility, dosage, safety and toxicity as well as efficacy of ex vivo expanded autologous T cells genetically modified to express anti-CD20 and CD19 immunoreceptor (MBCART2019.1) in patients with relapsed or resistant aggressive CD20 and CD19 positive B-NHL/CLL/SLL.

    Also known as: CD2019-targeting CAR T cells, Anti-CD2019 CAR T cells

  • BiologicalMB-CART2019.1 Dose level 2

    This is a prospective, multi-center, open phase I/II trial to evaluate feasibility, dosage, safety and toxicity as well as efficacy of ex vivo expanded autologous T cells genetically modified to express anti-CD20 and CD19 immunoreceptor (MBCART2019.1) in patients with relapsed or resistant aggressive CD20 and CD19 positive B-NHL.

    Also known as: CD2019-targeting CAR T cells, Anti-CD2019 CAR T cells

06

What researchers measure

Primary outcomes

  1. Determination of the maximum tolerated dose of MB-CART2019.1

    Determination of the MTD, defined as the highest dose level at which \<33% of patients experience DLT until day 28 after infusion of MB-CART2019.1 or 2.5x106 MB-CART2019.1 per kg BW, whichever occurs first.

    Time frame: Day 28 after infusion of MB-CART2019.1

  2. Safety and toxicity assessment of MB-CART2019.1

    Safety and toxicity assessment per AE reporting classified according to CTCAE Version 5.

    Time frame: Day 28 after infusion of MB-CART2019.1

Secondary outcomes

  1. Preliminary evidence of response to treatment

    Objective response rate: (sum of CR+PR), CR, PR, SD and PD is defined according to Lugano criteria (DLBCL, FL. MCL) or IWCLL criteria (CLL/SLL)

    Time frame: Weeks 4, 12, months 6 and 12 after infusion of MB-CART2019.1

  2. Phenotype and persistence of MB-CART2019.1

    Blood samples for determination of persistence/phenotyping of infused MB-CART2019.1 will be analysed

    Time frame: Days 2, 6, 9; Weeks 2, 3, 4, 6, 8, 12, months 6, 9, and 12 after infusion of MB-CART2019.1

  3. Overall Survival

    Determination of Overall Survival rate (OS) after Infusion of MB-CART2019.1

    Time frame: 12 months after infusion of MB-CART2019.1

  4. Best Overall Response (BOR)

    Best Overall Response recorded to study treatment after infusion of MB-CART2019.1 per Investigator assessment

    Time frame: Weeks 4 + 12, months 6 + 12 after infusion of MB-CART2019.1

  5. Occurence of B-cell aplasia

    Assessment of blood samples for occurrence of B cell aplasia

    Time frame: weeks 2, 4, 8, 12; months 6, 9, 12 after infusion of MB-CART2019.1

07

Study locations

3 sites
  • Klinikum Augsburg, II. Med. Klinik Haematologie / Onkologie
    Augsburg, Bavaria 86156, Germany
  • University Hospital Cologne - Department for Internal Medicine I
    Cologne, NRW 50937, Germany
  • Universitätsklinikum Hamburg-Eppendorf, Department of Stem Cell Transplantation
    Hamburg, 20246, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Dec 2020, 21 months.

Of 90 industry-sponsored phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's 21 months is below that.

Counting every sponsor, half of 207 studies reached it within 51 months; a quarter within 37 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2019
First posted
Mar 12, 2019
StartActual
Feb 25, 2019
Primary completionActual
Dec 17, 2020
CompletionActual
May 28, 2024
Last update
May 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03870945
Lead sponsor
Miltenyi Biomedicine GmbH
Collaborators
ICON plc
Responsible party
Sponsor
First posted
Mar 12, 2019
Start date
Feb 25, 2019
Primary completion
Dec 17, 2020
Completion
May 28, 2024
Last update
May 28, 2025

Study contacts

Peter Borchmann, Prof. Dr.
principal investigator · University Hospital Cologne

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion